MedTrace Logo

Preoperative levosimendán and Hip Fracture

NCT02972918 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2020-02-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether preoperative optimization with levosimendan in heart failure patients undergoing hip fracture surgery improves haemodynamic and tissue perfusion parameters.

Conditions

  • Ventricular Dysfunction, Left
  • Hip Fracture

Interventions

DRUG

Levosimendan

24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)

Sponsors & Collaborators

  • Orion Corporation, Orion Pharma

    collaborator INDUSTRY

  • Hospital Universitario de Canarias

    lead OTHER

Principal Investigators

  • María del Carmen Martín Lorenzo, MD · Hospital Universitario de Canarias

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-09-30
Completion
2019-04-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02972918 on ClinicalTrials.gov